Matthew Parris

Chief Tech/Sci/R&D Officer at TRAWS PHARMA, INC.

Health Technology

Consumer Services

Profile

Matthew Parris is currently working as the Vice President-Clinical Operations at Traws Pharma, Inc. He previously worked as the Director-Clinical Operations at Aegerion Pharmaceuticals, Inc. and Inovio Pharmaceuticals, Inc. He also held the position of Vice President-Clinical Development at Eleison Pharmaceuticals, Inc. Mr. Parris completed his undergraduate degree at Imperial College London.

Matthew Parris active positions

Companies	Position	Start
TRAWS PHARMA, INC.	Chief Tech/Sci/R&D Officer	2018-07-31

All active positions of Matthew Parris

Former positions of Matthew Parris

Companies	Position	End
Eleison Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ.	Corporate Officer/Principal	-
AEGERION PHARMACEUTICALS, INC.	Corporate Officer/Principal	-
INOVIO PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

See the detail of Matthew Parris's experience

Training of Matthew Parris

Imperial College London

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Matthew Parris's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
TRAWS PHARMA, INC.	Health Technology
INOVIO PHARMACEUTICALS, INC.	Health Technology

Private companies	2
Aegerion Pharmaceuticals, Inc. Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA.	Health Technology
Eleison Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ.	Health Technology